Table 4 The secondary KRAS mutation rate stratified by treatment regimens with or without cetuximab in Group A, Group B, and Group C.

From: Retrospective stratified analysis of resistance mechanisms to anti-EGFR therapy in mCRC using tumor tissue samples

Group

Chemotherapy

Chemotherapy plus cetuximab

Total

Group A

0% (0/12)

0% (0/1)

0% (0/13)

Group B

0% (0/7)

0% (0/9)

0% (0/16)

Group C

0% (0/5)

18.8% (3/16)

14.3% (3/21)

Total

0% (0/24)

11.5% (3/26)

6.0% (3/50)

  1. Group A, adjuvant chemotherapy and recurrence group; Group B, first-line chemotherapy without progression group; Group C, first-line chemotherapy with progression group.
Back to article page